Drives HCC lung metastasis
FBXL6 is a key driver of HCC metastasis, far surpassing Kras mutation, p53 haploinsufficiency, or Tsc1 loss in promoting metastasis, offering a novel therapeutic target for metastatic HCC.
Zhang, Jie · Lin, Xiao · Yu, Qiang · Fang, Lei · Wu, Di · Yuan Hui Luo, · Yu-Jun, Zhang · Xie, Chuanming
Experimental and Molecular Medicine 2023
FBXL6 is a much stronger driver of HCC lung metastasis than Kras mutation, p53 haploinsufficiency, or Tsc1 loss
Targeting or knockdown of TKT significantly blocked FBXL6-driven immune evasion and HCC metastasis
In HCC patients, active TKT levels are increased and positively correlated with FBXL6 and VRK2 expression